Dacetuzumab is a humanized anti-CD40 MoAb that works by downregulating interleukin-6 (IL-6) receptor, making cells unresponsive to IL-6 stimulation, and inducing cell death in MM cell lines (Tai et al., 2005). Here, CD40 is linked to Miyoshi myopathy.